Department of Justice
Drug Enforcement Administration
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 29, 1999, Ansys Diagnostics, Inc., 25200 Commercentre Drive, Lake Forest, California 92630, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
The firm plans to manufacture the listed controlled substances to produce standards and controls for in-vitro diagnostic drug testing systems.
Any other such application and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than April 17, 2000.
| Drug | Schedule |
|---|---|
| Phencyclidine (7471) | II |
| 1-Piperidinocyclohexane- carbonitrile (PCC) (8603) | II |
| Benzoylecgonine (9180) | II |
Dated: February 10, 2000.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.